MSD claims EU approval for two HIV products

In the US, Merck has priced Delstrigo at $70 per day, at the low end of rivals such as Gilead’s Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) and ViiV’s Triumeq

GSK’s says depot HIV injection works over three years

FLAIR is looking at monthly dosing in treatment-naïve patients who have their virus levels controlled initially using ViiV’s three-drug Triumeq (abacavir/dolutegravir/lamivudine) product.

ViiV chalks up another win for two-drug HIV regimen

few years due to the success of drugs like oral integrase inhibitor Tivicay (dolutegravir) and triple regimen Triumeq (dolutegravir/lamivudine/abacavir).

GSK two-drug trial in untreated HIV raises Gilead rivalry

years due to the success of drugs like Tivicay and triple regimen Triumeq (dolutegravir/lamivudine/abacavir).

1 2 3 4 5 6 7 [ Next 5 results ]